Psoriasis

Dra. Lara Ferrándiz
• Anti-IL 23
  • Mirikizumab
  • Risankizumab
  • Guselkumab
  • Tildrakizumab

• Anti-IL 17
  • Bimekizumab
  • Ixekizumab
  • Secukinumab
  • Brodalumab

• Anti-IL 12-23
  • Ustekinumab

• AntiTNF
  • Infliximab
  • Etanercept
  • Adalimumab
  • Certolizumab

• Anti PDE4
  • Apremilast

• Biosimilares de antiTNF

• Fumaratos
Anti-IL23

- Mirikizumab (EC NCT02899988)
  - >60% PASI90 responders in week 16

- Risankizuab
  - the good results are regardless of baseline demographics or disease characteristics

- Tildrakizumab (EC NCT01729754)
  - Tildra 200mg in ETN non-responders resulted in PASI75 response in 9/10 patients and PASI90 in 4/10
Anti-IL17

- **Bimekizumab (NCT02905006)**
  - PASI90 at week 12 was achieved by significantly more patients compared with placebo
  - Up to 60% of patients achieved complete clearance at week 12

- **Brodalumab**
  - Head and neck showed the most rapid response and lower limbs the slowest. Complete clearance of head and neck: 91%.
Biosimilars

• Biosimilar BI695501 – adalimumab (NCT02850965)
  • BI695501 and adalimumab reference product demonstrated similar efficacy in terms of PASI75 at week 16

• Biosimilar SB4 – etanercept
  • The real-world data from BADBIR show that SB4 is effective for patients with psoriasis